Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats hormone receptor (HR)-positive, human epidermal growth factor receptor 2…. Sold as Etcamah. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Camizestrant (sold as Etcamah), first approved Sep 4, 2026, with 0 new uses approved and 0 published complete response letters.
First approved: Sep 4, 2026
Applications: 1
New uses approved: 0
Complete response letters: 0
First approved in the EU: Jul 20, 2026
Approvals in the EU (EMA)
First approved in the EU 2 months before the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Astrazeneca